Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 151–160 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 151
- Medicine slug
- azathioprine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
30%
- Numeric value
- 30
- Unit
- %
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f994aed-f8e7-4967-a167-b22b783b4192 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9f91b9-7959-65e7-e063-6294a90a3680 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable see OVERDOSAGE .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f3219f-898f-4d05-a430-c2b3f5255af1 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5116b22b-1460-5535-e063-6394a90acbe5 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9050af7a-19c6-4670-937a-9445605de995 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4c7d621-9642-4027-e053-2995a90a9220 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc6dc4bd-2121-4613-9d90-4a504010c98a (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8429e025-b79d-dae7-e053-2a91aa0a7fe5 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f93d9408-7b3f-b423-e053-6294a90a31ec (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d72ede2c-1a9b-4717-80a7-b76a6a499936 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:606101a0-6244-7eff-e053-2a91aa0acadd (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d288e484-32fc-4b46-b504-d75a0fac8663 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ffa2fce-895d-469e-8667-b078560aec5f (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceab8e8b-d022-4d0c-a552-cc5782446248 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49b7cc5-0eed-43b7-b7ad-cbb1b6f0cd2c (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable (see OVERDOSAGE ).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f251f372-c881-483e-8035-c6a8a6bfb4e8 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0fa3e-11c3-46d0-9537-6b372c2a1b56 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable see OVERDOSAGE .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:040d010a-b1b2-4db7-905d-8aa7f1bab0cd (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable see OVERDOSAGE .
Projected row 152
- Medicine slug
- azelastine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02257284-4bb1-4fe6-8134-e5a67a645114 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97c91a09-98d0-4666-8448-0bd50c02bb14 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d031d-428d-4d53-8e63-feb96d5ab01a (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7902605c-944a-4d7e-a7d4-eb4a71bcacdb (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine HCl is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:305c6dc8-8247-473d-9975-b02903af6d53 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f58c203-f649-a18e-aaf3-70b0797652f4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb0aca6d-ff9c-4239-8681-d212a6764ba9 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c40f8d-269c-4df8-8ac7-cbe78f4ca5c4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77b20c6b-f30f-42a9-a0ef-d5d0bd3feb56 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba9c1d-b21f-4816-bbe6-949a49e38572 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a74cae-a15b-4a6b-a8c0-1e6a234ee258 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
At a dose approximately 8 times the maximum recommended dose, azelastine hydrochloride does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics Absorption After intranasal administration, the systemic bioavailability of azelastine hydrochloride is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca75501-4140-4d77-e053-2a95a90a019f (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: After intranasal administration, the systemic bioavailability of azelastine HCl is approximately 40%.
Projected row 153
- Medicine slug
- azelastine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
22 hours
- Numeric value
- 22
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02257284-4bb1-4fe6-8134-e5a67a645114 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97c91a09-98d0-4666-8448-0bd50c02bb14 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d031d-428d-4d53-8e63-feb96d5ab01a (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7902605c-944a-4d7e-a7d4-eb4a71bcacdb (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:305c6dc8-8247-473d-9975-b02903af6d53 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f58c203-f649-a18e-aaf3-70b0797652f4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb0aca6d-ff9c-4239-8681-d212a6764ba9 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c40f8d-269c-4df8-8ac7-cbe78f4ca5c4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77b20c6b-f30f-42a9-a0ef-d5d0bd3feb56 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba9c1d-b21f-4816-bbe6-949a49e38572 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a74cae-a15b-4a6b-a8c0-1e6a234ee258 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca75501-4140-4d77-e053-2a95a90a019f (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Elimination: Based on intravenous and oral administration, the elimination half-life and plasma clearance are 22 hours and 0.5 L/h/kg, respectively.
Projected row 154
- Medicine slug
- azelastine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
88%
- Numeric value
- 88
- Unit
- %
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02257284-4bb1-4fe6-8134-e5a67a645114 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97c91a09-98d0-4666-8448-0bd50c02bb14 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d031d-428d-4d53-8e63-feb96d5ab01a (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7902605c-944a-4d7e-a7d4-eb4a71bcacdb (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:305c6dc8-8247-473d-9975-b02903af6d53 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f58c203-f649-a18e-aaf3-70b0797652f4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb0aca6d-ff9c-4239-8681-d212a6764ba9 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72406ded-7886-41fb-b5c8-2d27a149aa34 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:753d7a69-b0da-4350-9dc5-97f26ebe5cc0 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c40f8d-269c-4df8-8ac7-cbe78f4ca5c4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77b20c6b-f30f-42a9-a0ef-d5d0bd3feb56 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04e5eede-17ff-4765-af77-d46c139da703 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba9c1d-b21f-4816-bbe6-949a49e38572 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6945fb86-27fb-4bab-8908-98772c6269c5 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a33738-ffcf-221c-1562-780418882e5d (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97% respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ae2aec7-329b-41bf-89d5-f189afb782ee (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a74cae-a15b-4a6b-a8c0-1e6a234ee258 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f358cecd-284f-4d0b-806c-039465220bd2 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca75501-4140-4d77-e053-2a95a90a019f (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.
Projected row 155
- Medicine slug
- azelastine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
14.5 L/kg
- Numeric value
- 14.5
- Unit
- L/kg
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02257284-4bb1-4fe6-8134-e5a67a645114 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97c91a09-98d0-4666-8448-0bd50c02bb14 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc9d031d-428d-4d53-8e63-feb96d5ab01a (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7902605c-944a-4d7e-a7d4-eb4a71bcacdb (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:305c6dc8-8247-473d-9975-b02903af6d53 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f58c203-f649-a18e-aaf3-70b0797652f4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb0aca6d-ff9c-4239-8681-d212a6764ba9 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72406ded-7886-41fb-b5c8-2d27a149aa34 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:753d7a69-b0da-4350-9dc5-97f26ebe5cc0 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c40f8d-269c-4df8-8ac7-cbe78f4ca5c4 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77b20c6b-f30f-42a9-a0ef-d5d0bd3feb56 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution : Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04e5eede-17ff-4765-af77-d46c139da703 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ba9c1d-b21f-4816-bbe6-949a49e38572 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6945fb86-27fb-4bab-8908-98772c6269c5 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a33738-ffcf-221c-1562-780418882e5d (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ae2aec7-329b-41bf-89d5-f189afb782ee (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11a74cae-a15b-4a6b-a8c0-1e6a234ee258 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f358cecd-284f-4d0b-806c-039465220bd2 (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bca75501-4140-4d77-e053-2a95a90a019f (opens source in a new tab)
Azelastine label
Version not recorded · Effective date not recorded
Distribution: Based on intravenous and oral administration, the steady-state volume of distribution is 14.5 L/kg.
Projected row 156
- Medicine slug
- azilsartan-kamedoxomil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
11 hours
- Numeric value
- 11
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b27c75-9f5a-4816-bafd-dace9d7d2063 (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c09103d8-c094-473d-a303-bbb4f334aa8c (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min.
Projected row 157
- Medicine slug
- azilsartan-kamedoxomil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b27c75-9f5a-4816-bafd-dace9d7d2063 (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c09103d8-c094-473d-a303-bbb4f334aa8c (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin.
Projected row 158
- Medicine slug
- azilsartan-kamedoxomil
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1.5 to 3 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b27c75-9f5a-4816-bafd-dace9d7d2063 (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
After oral administration of azilsartan medoxomil, peak plasma concentrations (C max ) of azilsartan are reached within 1.5 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c09103d8-c094-473d-a303-bbb4f334aa8c (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
After oral administration of azilsartan medoxomil, peak plasma concentrations (Cmax) of azilsartan are reached within 1.5 to 3 hours.
Projected row 159
- Medicine slug
- azilsartan-kamedoxomil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
16 L
- Numeric value
- 16
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b27c75-9f5a-4816-bafd-dace9d7d2063 (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of azilsartan is approximately 16 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c09103d8-c094-473d-a303-bbb4f334aa8c (opens source in a new tab)
Azilsartan Kamedoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of azilsartan is approximately 16 L.
Projected row 160
- Medicine slug
- azithromycin
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 162
- Source count
- 147
- Agreement rate
- 0.931973
- Recorded readings
38%
- Numeric value
- 38
- Unit
- %
- Source records
- 137
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 137 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ab854bf-eb04-42c4-a403-096b60581bb4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d564d91e-3039-c120-e053-2995a90ae6db (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b08bd8fc-20da-4623-9211-ae669452b16d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f36ba37-a742-41c1-ad2d-b890a1d49c55 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45410338-6bff-476b-b8e1-6c6238205a99 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1755cf3-bf7f-be40-e053-2a95a90a8536 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc99fae-a72c-8893-e063-6394a90aa3ef (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47a8fd64-5a3d-490e-8ca8-5e6721c830cf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:405ab07f-7d1d-4552-ad3b-2a03be8e9949 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24c07398-84ad-48e2-9625-e9073c28fb73 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:943b9246-7733-44b1-875c-91d2ade78ac4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7ed6985-1d1d-48af-9df8-64b12821789e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ed68b5a-4093-49f1-871b-7b0da5f7be2d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8037c6f4-4881-4740-8229-2aee56141cd0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:661ff7a6-6394-493d-a307-a1f607e5d117 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f144e92-c9eb-420a-9bb8-4265a9f20a98 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6caeda98-7020-413a-9461-04f476dad4ba (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:882f71b1-b153-4856-b4a7-1a29ae9cf247 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a52c0b-45db-422e-8c22-e867a11b4439 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d0a4eb-5076-65c6-e063-6394a90ac13a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
5 C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of ZITHROMAX 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0138503-ddc4-2e1c-e053-2995a90a0d2d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99ca0089-14a9-446d-8807-253ad5be3efa (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf098d5-dfd5-4a0d-81f7-6afa1a203a27 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6169e56c-10fb-448d-ab0f-14e54fcf2817 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3745a0b0-7855-69eb-e063-6294a90ab6a8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6fb42ed-7dac-4a7b-9964-d367dd47dd5c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6426d5f-5518-3c69-e053-2995a90af50f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Cmax (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC0–∞ (mcg∙hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc633b7d-5154-7e43-e053-2a95a90ad2a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b7e16b1-9a3c-4e3a-8411-841a708afe45 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21c67de0-3a4e-caab-e063-6394a90ae3cd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c44af6d-8a9a-cb4c-e053-2a95a90afdac (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81212ef-76b6-4bd7-8706-3d2b05ee34f9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df9b39b7-d42d-4c4b-b492-9fd228978dec (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b43d23c7-1a2e-ce93-e053-2995a90a65a4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549cdd0a-da79-23b8-e054-00144ff8d46c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34e6364a-ac3d-434e-a90c-cb13ebcf7983 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c95c30-564f-4b67-ac6d-9179cdfaa5a8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba57ff26-cd02-4f57-ac92-b613d245a4ea (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4278e306-bc26-4282-93ce-f1405e0b5d4a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f97d2e7e-ccfd-4f04-85ba-549b37f6aa7b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2065c4ba-e3f5-41a2-b3d5-205dab646924 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e2163b-af61-4323-8b9c-2d44fc122fd9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f7c7421-411d-c04e-e063-6394a90a4aa0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4196e616-bdd8-9e88-e063-6394a90ac81d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac327054-21ab-401c-a27a-48259db18f89 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77c5e4c6-6d16-40fe-bf36-cb441348f39b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5d79719-b1dc-469f-a19c-f8ba615138f0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d78cd8e-0c63-46d6-b018-939fcbbe42a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c4861f2-825e-4e3b-9907-9658a849079e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c926669-62b2-4ad3-8289-173c5818a9c1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:397471e5-76e2-462c-af30-bcc54fe00266 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5b4092d-ab72-f5d1-e053-2995a90ac582 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
y 5 Cmax (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC0-∞ (mcg∙hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ddecd25-dc32-a2af-e063-6294a90a526d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94e17ae5-0871-67a0-e053-2995a90ae0ae (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c902990-b870-4725-b9fe-76b8be633e1c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af720986-48a9-48b5-bdd7-370f6a2f92e1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b821631-0df2-0fb2-e054-00144ff8d46c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:826f9c07-8eb9-a128-e053-2991aa0ad654 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8389c336-25eb-a96f-e053-2a91aa0a0dd8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edecf20d-c681-418b-9c47-02fb32d2b3c0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90605f94-93e1-43d1-8be7-830e816ac84f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9800bbe-e8bf-4689-a8a5-dc23b5d2ee56 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3c84aea-7ba7-4aae-999c-db740a9e53df (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e4fbd52-43e4-4d87-a136-f4d680a8d0c1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
5 C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ mcg∙hr/mL) 17.4 (6.2) * 14.9 (3.1) * Serum T ½ 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8010dc-700f-45d3-94ca-ebe4a51acc1b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58308e8b-57bd-4e82-a2e8-24aac63194cd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f9e13f5-69ee-4220-90d9-31fa8660d880 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a2bdcb-3012-42fb-ac66-d1d879100940 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82454fb2-e524-ecb8-e053-2991aa0a6e7c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20ae108a-00c5-a984-e063-6394a90aaaae (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4c05e22-4a54-4948-abf8-8a479d465d30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb97a057-2537-41ae-b50c-a80605039c30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7711e846-0bb3-486c-8511-f445e264cd98 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:714f6f55-278a-4fcf-8d4e-2ad9b43623a3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e7184e1-3c3c-cd87-e053-2a95a90a6eb6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9270e676-3382-6483-e053-2a95a90a556e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a4d2b3-daea-4d96-891f-4b9823629456 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8e106cb-7245-45a5-9aad-bd624b1e011d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25bc2e78-9d0d-41c6-a55e-a267d4457967 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd1f4b5-6c32-3075-e063-6294a90a0d4b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c9de2e9-c20c-4660-a272-a22019f9fb02 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333ffe63-aaeb-4dff-b595-1c11209189a6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d4ac05-b564-440c-971d-b78590dd2c32 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of ZITHROMAX 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1172805-0930-4fb9-8a2f-e0d6a0430630 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25f2d819-ae38-4061-a897-bbcfce3739bf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33140df5-420d-469f-b6c8-121e952a5cb6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:258dd3c5-dce9-7483-e063-6294a90a4043 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e6e11fb-eb9e-28ec-e053-2a95a90aa1a3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
y 5 Cmax (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3209b147-11ce-4eeb-8427-5f8e6fb2c83d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4314da8a-40e5-4aba-a32b-57b4166ade30 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf061799-cdef-40f8-b1ce-bc5eb609f8c3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f52ce0-ad3f-7d80-e063-6294a90ad086 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b90572c-cc24-49f0-baaf-09022a2f9a00 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de5b0c2b-9a7d-46e9-8169-4100442efa9b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:003307c5-3f73-4a5d-a704-bfdea3c656e8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea128124-8712-4998-be46-47d43ef127d4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:510024c9-6658-e08f-e063-6294a90a0793 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76093152-e2d7-4fe1-8568-1f0fec1747c2 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9cdb5ae-2aeb-c598-e053-2a95a90a8062 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec619299-e0ef-44dd-acdb-8c53bbfc5b8a (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99e5bd22-a721-4e2e-a46c-d61a53c25c3d (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:859bb02c-a4bc-46fa-9fc9-def1219b5dfb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fd25741-f014-3999-e063-6394a90acdd0 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f0501bf-d1c4-46a5-b253-3b9e61015e82 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deea1a56-84ed-4ce4-9d11-03271510c0a1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a506cd-aae7-a622-e053-2a95a90ad352 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1752913-85ac-01fa-e053-2995a90a2bd8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e7c2f49-449c-4ba2-98ae-0ff0c040614c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da399401-1ee6-422a-be46-0bba6b264b2f (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b635019e-7fd4-7f9e-e053-2a95a90a388c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0cfda1a-910f-4764-8658-263037df5ea8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60ec2020-148b-4a2a-96f2-dd09c590ecbb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1c96531-bbd2-4dc5-8eeb-3f0276cd0956 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9b66736-3f1a-4d6d-bdc4-274f5adfb40c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:795c13cd-e9ca-481b-9fa9-2890bdf9dac8 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01649d79-4677-4577-a3e4-e054f3f9fc3b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4eec460d-5ba8-4614-8700-219a9b4fc385 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b77b347d-d357-4bdf-b985-49d9a1dd634c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44134421-cb0b-4e85-a3c8-d58bdb476fad (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb40f4cf-15ae-47ab-8e0a-979467fa0d9e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb2f83a2-507b-4cf3-81ea-d10c46c0f8ea (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39a808c4-72ac-48e4-bfb8-e5ae3429b225 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90ff7cfc-73c9-4d77-83df-c05cfbbbbecd (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3761d39-9b79-4908-8b05-a1c91e599998 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:896cce83-23ac-f4ed-e053-2a95a90ad107 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c84a68b-3eaa-4dab-b5e5-e195c7652e67 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cec44fa-9597-3e58-e063-6394a90ae326 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
x (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0 - ∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1 / 2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f175496a-4ad3-ce0d-e053-2a95a90a6613 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38942011-f86b-4e42-a4ca-05a70d9dd3d9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2b0c06b-e93d-f5aa-e053-2995a90ac9aa (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11446677-a3dc-40cb-897d-7a9851b8c89c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59c4b783-4ff7-4269-969b-58a10e12b12b (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3962bc34-8236-4ac1-8ffd-2edbd430c3eb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5199689f-8881-7757-e063-6394a90ae2eb (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db52b91e-79f7-4cc1-9564-f2eee8e31c45 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
43 (0.20) 0.24 (0.06) Serum AUC 0–∞ (mcg∙hr/mL) 17.4 (6.2) Total AUC for the entire 3-day and 5-day regimens. 14.9 (3.1) Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:814abe38-da4a-48af-bf4b-2ce04a5aabd1 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
C max (serum, mcg/mL) 0.44 (0.22) 0.54 (0.25) 0.43 (0.20) 0.24 (0.06) Serum AUC 0-∞ (mcg·hr/mL) 17.4 (6.2)* 14.9 (3.1)* Serum T 1/2 71.8 hr 68.9 hr Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:614cc2a4-3fc7-455d-9e8a-212c496f0fbf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of azithromycin 250 mg capsules is 38%.
34%
- Numeric value
- 34
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90e65b83-32d6-40bc-be5d-19fbec051bdf (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac549022-4d7f-4c9f-9244-1a2df9a27276 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dca5a11-3c02-4a51-a35d-f91f37b8e00c (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9990a1d-5238-403e-9221-72a9314d7b5e (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b88f5839-8e8b-4bf6-a577-5c8b7cffeec6 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV = 56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2754618-3df1-4b89-aa09-fdff4b71b7e4 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV = 56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d5129e4-8b94-4a4d-baa9-be0d6b32d714 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV = 56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b70c23-92a6-460f-8dbb-15a0e6b9d3a9 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc93e72-95ce-965b-e063-6394a90a8917 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16da30a2-d11c-7e8c-e063-6294a90a62e3 (opens source in a new tab)
Azithromycin label
Version not recorded · Effective date not recorded
The absolute bioavailability of two 600 mg tablets was 34% (CV=56%).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=150Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.